| Literature DB >> 31603079 |
Hirdaya Hulas Nag1, Ashish Sachan1, Phani Kumar Nekarakanti1.
Abstract
INTRODUCTION: The outcome of laparoscopic extended cholecystectomy (EC) with wedge hepatic resection (LECW) in patients with gallbladder cancer (GBC) has been compared with that of open EC with wedge hepatic resection (OECW), but studies comparing laparoscopic EC with bi-segmentectomy (LECB) with open EC with bi-segmentectomy (OECB) are lacking. PATIENTS AND METHODS: This retrospective study comprised of 68 patients with GBC who were offered either LECB or OECB from July 2011 to July 2018. Patients were divided into laparoscopic group (LG) and open group (OG), and appropriate statistical methods were used for comparison.Entities:
Keywords: Bi-segmentectomy; extended cholecystectomy; gallbladder cancer; laparoscopic; laparoscopic versus open; radical cholecystectomy
Year: 2021 PMID: 31603079 PMCID: PMC7945642 DOI: 10.4103/jmas.JMAS_98_19
Source DB: PubMed Journal: J Minim Access Surg ISSN: 1998-3921 Impact factor: 1.407
Figure 1(a) Port position. (b) Excision of regional lymph nodes. (c) Dissection of hepato-cystic triangle with inset showing excision of cystic duct margin for frozen biopsy. (d) Ligation of portal pedicle to hepatic segment 4b with inset showing transaction of parenchyma (s4b) along the demarcation line. (e) Ischaemic demarcation line after ligation of portal pedicle to hepatic segment 5. (f) Liver surface after completion of bi-segmentectomy s4b and s5 with inset showing resected specimen
Comparison of demographic, clinical, operative and postoperative parameters
| Parameters | Lap ( | Open ( | |
|---|---|---|---|
| Age (years), mean±SD | 49.6±12.8 | 49±10.1 | 0.838 |
| Sex (male), | 3 (10) | 15 (39.4) | 0.011 |
| Comorbidity, | 7 (23.3) | 5 (13.1) | 0.344 |
| Incidental GBC, | 11 (36.6) | 6 (15.7) | 0.089 |
| Serum bilirubin (mg/dl), mean±SD | 0.5±0.2 | 0.9±1.2 | 0.076 |
| Preoperative haemoglobin (g/dl), mean±SD | 10.6±1.5 | 11.4±2.3 | 0.133 |
| Serum albumin (mg/dl), mean±SD | 3.7±0.5 | 3.7±0.5 | 0.811 |
| Serum CA19-9 (U/ml), mean±SD | 15.9±21.5 | 20.2±35.1 | 0.561 |
| Blood loss (ml), mean±SD | 158.6±85.7 | 219.4±87.7 | 0.006 |
| Duration of surgery (min), mean±SD | 286.5±71.6 | 274.2±96.3 | 0.565 |
| Hospital stay (days), mean±SD | 6.4±3.1 | 9±8.0 | 0.0001 |
| Additional procedure performed, | 5 (16.6) (bile duct excision: 3, segmental colonic + duodenal resection: 1, colonic sleeve resection: 1) | 11 (28.9) (bile duct excision: 6, bile duct excision + distal gastrectomy: 1, colonic resection: 3, segmental duodenal resection: 1) | 0.266 |
| Complications, | |||
| Overall | 5 (16.6) | 12 (31.5) | 0.259 |
| Grade I | 3 (10) | 5 (13.1) | |
| Grade II | 2 (6.6) | 3 (7.8) | |
| Grade III | 0 | 1 (2.6) | |
| Grade IV | 0 | 2 (5.2) | |
| Grade V | 0 | 1 (2.6) |
GBC: Gallbladder cancer, SD: Standard deviation, CA: Carbohydrate antigen, LG: Laparoscopic group, OG: Open group
Comparison of oncological outcome and survival
| Parameters | LG ( | OG ( | |
|---|---|---|---|
| Lymph nodes, mean±SD | 11.9±5.2 | 12.7±4.2 | 0.503 |
| Negative margins (R0), n (%) | 30 (100) | 37 (97.3) | 0.9 |
| Minimum hepatic margin, (mm), mean±SD | 13.5±5.8 | 15.9±12.2 | 0.371 |
| GBC stage (AJCC 8th Ed.), | |||
| Stage 1 | 8 (26.6) | 5 (13.1) | 0.556 |
| Stage 2 | 8 (26.6) | 12 (31.5) | |
| Stage 3 | 10 (33.3) | 16 (42.1) | |
| Stage 4 | 4 (13.3) | 5 (13.1) | |
| T stage, | T1: 8 (26.6) | 6 (15.7) | 0.530 |
| T2:12 (40) | 17 (44.7) | ||
| T3:8 (26.6) | 15 (39.4) | ||
| T4:2 (6.6) | 0 (0) | ||
| N stage, | N0: 20 (66.7) | 25 (65.7) | 0.732 |
| N1: 7 (23.3) | 7 (18.4) | ||
| N2:3 (10) | 6 (15.7) | ||
| Histological type | |||
| Adenocarcinoma | 25 | 30 | 0.206 |
| Adenosquamous | 0 | 4 | |
| Intracystic papillary | 4 | 4 | |
| Neuroendocrine | 1 | 0 | |
| Tumour differentiation | |||
| Well differentiated | 11 | 8 | 0.045 |
| Moderately differentiated | 19 | 24 | |
| Poorly differentiated | 0 | 6 | |
| Vascular/lymphatic microinvasion | |||
| Yes | 8 | 13 | 0.504 |
| No | 22 | 25 | |
| Fundus | 17 | 23 | 0.534 |
| Fundus and body | 6 | 5 | |
| Body | 5 | 4 | |
| Neck | 2 | 6 | |
| Recurrence, | 6 (20) | 11 (28.9) | 0.410 |
| Local recurrence, | 4 (13.3) | 6 (15.7) | 0.627 |
| Distant metastasis, | 2 (6.7) | 5 (13.1) | |
| Adjuvant treatment, | 15 (50) | 19 (50) | 1.0 |
| Median follow-up (months) | 24 | 36 | 0.0001 |
| RFS (months), mean±SE | 48.6±4.1 | 44.6±3.8 | 0.352 |
| Overall survival (months), mean±SE | 51.0±3.58 | 46.4±3.39 | 0.457 |
| One-year survival (%) | 96 | 94 | 0.457 |
| Three-year survival (%) | 79 | 72 | |
| Five-year survival (%) | 79 | 62 |
GBC: Gallbladder cancer, SE: Standard error, LG: Laparoscopic group, OG: Open group, AJCC: American Joint Committee on Cancer, RFS: Recurrence-free survival
Figure 2(a) Recurrence-free survival curve. (b) Overall survival curve